These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34583091)

  • 1. Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
    Regmi P; Hu HJ; Lv TR; Paudyal A; Sah RB; Ma WJ; Jin YW; Li FY
    Surg Oncol; 2021 Dec; 39():101663. PubMed ID: 34583091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
    Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M
    J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
    Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong S; Yu H; Wang H; Song J; Yan J
    Clin J Gastroenterol; 2023 Dec; 16(6):793-802. PubMed ID: 37740882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
    Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K
    BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
    Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
    PLoS One; 2019; 14(6):e0218136. PubMed ID: 31194789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Long Y; Song X; Guan Y; Lan R; Huang Z; Li S; Zhang L
    J Gastroenterol Hepatol; 2023 Apr; 38(4):486-495. PubMed ID: 36516040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
    Kang MK; Park JG; Lee HJ
    Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
    JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K
    J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
    Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y
    Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C; Fu Y; Li W; Zuo M; Wu P
    Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.